Nimotop® Tablets for Subarachnoid Hemorrhage

Nimotop is an oral nimodipine medicine used after aneurysmal subarachnoid hemorrhage. It helps lower the risk of delayed brain injury from vessel spasm. Ships from Canada to US, and Canadian pricing may help if paying without insurance.

What Nimotop Is and How It Works

Nimotop® contains nimodipine, a dihydropyridine calcium channel blocker with a preferential effect on cerebral arteries. By limiting calcium entry into vascular smooth muscle, this medicine can help reduce cerebral vasospasm after a ruptured aneurysm. The treatment is used as part of comprehensive care to improve neurological outcome following subarachnoid hemorrhage.

Nimotop 30 mg tablets are for oral use only. Do not administer this medicine by intravenous routes. Follow the official label and your care team’s instructions if administration through feeding tubes is considered in inpatient settings.

CanadianInsulin.com is a prescription referral platform. We verify prescriptions with your prescriber when required, and licensed Canadian pharmacies dispense your order.

Who It’s For

This therapy is indicated for adults following aneurysmal subarachnoid hemorrhage to reduce the severity of ischemic neurological deficits. It is commonly initiated in a monitored setting and continued during the early recovery period. It is not a treatment for acute bleeding control and is not indicated for routine hypertension management.

People with significant hypotension, advanced hepatic impairment, or known hypersensitivity to nimodipine should not use this product unless a prescriber determines potential benefit outweighs risk. Use caution in patients taking other blood pressure–lowering therapies. Pregnancy and breastfeeding considerations require clinician guidance based on the official label.

Dosage and Usage

Standard schedules on the label use frequent dosing over a 21‑day course after the hemorrhage. Timing of initiation and continuation are determined by hospital protocols and the prescriber. Swallow the tablets whole with water. Do not take with grapefruit or grapefruit juice because of interaction potential. If administration through a tube is being considered, defer to institutional procedures and the product monograph. Never inject this medicine.

Take doses consistently relative to meals if instructed, as absorption may vary. Blood pressure and neurological status are typically monitored during therapy, particularly early in the course. Do not change the schedule on your own; follow the prescriber’s plan.

Strengths and Forms

This product is supplied as oral film‑coated tablets in a commonly published strength of 30 mg. Availability and packaging can vary by manufacturer and pharmacy.

Missed Dose and Timing

If a dose is missed, take it when remembered unless it is close to the next scheduled time. Do not double up to replace a missed dose. Keeping doses evenly spaced helps maintain a steady effect during the post‑hemorrhage period.

Storage and Travel Basics

Store tablets at room conditions as directed on the label. Protect from light and keep them in the original container with the closure tightly in place. Keep out of reach of children and pets. When traveling, carry the labeled container in your hand luggage, along with your prescription details or a photograph of the label. Avoid high heat or excessive moisture, and do not store in a car glove box for extended periods.

For temporary pill organizers, keep the original bottle and paperwork with you for security screening or clinical visits. If your prescriber provided specific instructions for inpatient-to-home transitions, follow those and bring the medication list to follow-up appointments.

Benefits

This therapy belongs to a class that can reduce the risk of delayed cerebral ischemia related to vasospasm after aneurysmal subarachnoid hemorrhage. It is taken orally, allowing use during the early recovery period. Hospital teams often incorporate it into bundled care that includes monitoring, aneurysm repair, and supportive measures.

Side Effects and Safety

• Headache or lightheadedness
• Flushing or warmth
• Nausea or stomach discomfort
• Low blood pressure with dizziness
• Fast or slow heartbeat
• Peripheral swelling

Serious effects can include marked hypotension, pronounced heart rate changes, or symptoms of reduced cerebral perfusion. Intravenous administration of oral nimodipine products has caused fatalities and is contraindicated. Seek urgent care for severe dizziness, fainting, weakness, chest pain, or worsening neurologic signs. The label includes additional rare reactions and special population considerations.

Drug Interactions and Cautions

Strong CYP3A4 inhibitors can raise nimodipine exposure. Examples include certain azole antifungals, macrolide antibiotics, HIV protease inhibitors, and some antidepressants. Strong inducers, such as rifampin, carbamazepine, or phenytoin, can reduce exposure. Avoid grapefruit or grapefruit juice. Additive effects may occur with other blood pressure–lowering agents, including beta‑blockers or other calcium channel blockers. Hepatic impairment can increase exposure and requires prescriber guidance.

For a general overview of how different medicine classes work, see our article Common Diabetes Medications. Always defer to the nimodipine product label for interaction specifics relevant to this therapy.

What to Expect Over Time

The therapy is usually started soon after aneurysm repair or as part of early management and continued for several weeks. Clinical teams monitor blood pressure, neurologic status, and overall recovery. Patients may not feel a noticeable effect from each dose; its benefit is preventive and assessed by clinical outcomes over the course of care. Report symptoms such as severe dizziness, worsening headache, or new neurologic changes promptly to your care team.

Compare With Alternatives

Nimodipine is the only calcium channel blocker with a labeled indication for use after aneurysmal subarachnoid hemorrhage. Other agents in the class treat different cardiovascular conditions and are not substitutes for this indication. For context on class relatives carried by our pharmacy, compare Nifedipine and Verapamil. Any change requires prescriber direction.

Pricing and Access

Canadian pricing is shown on the product page with US delivery from Canada. To review current pricing and availability, check the listing and add the item to your cart when your prescription is ready. If you are exploring savings, compare cash‑pay options on the site. Checkout is encrypted, and your information is protected.

For condition‑specific options, browse our category Subarachnoid Hemorrhage SAH. Looking for seasonal offers or codes? See Promotions for current site updates.

Availability and Substitutions

Supply can vary by manufacturer and pack size. If the product is unavailable, a prescriber may recommend an alternative approach based on your clinical needs. We do not guarantee dates for restock. Check the listing for updates, or contact support for product status questions related to ordering steps.

Patient Suitability and Cost-Saving Tips

Adults recovering from aneurysmal subarachnoid hemorrhage may be candidates if a prescriber confirms it is appropriate. Those with significant hypotension, severe hepatic impairment, or major interacting therapies may require a different plan. For budget planning, consider multi‑month fills when approved, and align refill reminders with your follow‑up schedule so you can place your order on time. You can enable email alerts in your account to avoid gaps.

For broad health literacy topics in our library, visit Diabetes Education Week and Diabetic Eye Disease Month. These resources provide general care insights even if your condition differs.

Questions to Ask Your Clinician

• Timing and duration: when to start and stop therapy
• Monitoring plan: blood pressure checks and neurologic assessments
• Interaction risks: which medicines, foods, or supplements to avoid
• Hospital-to-home steps: administration and follow‑up coordination
• Side effects: what to watch for and when to seek care
• Hepatic considerations: any adjustments or extra precautions
• Recovery goals: how this therapy fits into overall management

Authoritative Sources

DailyMed: Nimodipine (Nimotop) Prescribing Information

Health Canada DPD: Nimodipine Product Monograph

Manufacturer: Bayer (Product Information)

Order through CanadianInsulin for prompt US shipping from Canada. This page is informational and does not replace advice from your healthcare professional.